Understanding SLC25A34: Potential Drug Targets for A Variety of Diseases

Target Name: SLC25A34

NCBI ID: G284723

SLC25A34

Other Name(s): S2534_HUMAN | RP11-169K16.2 | solute carrier family 25 member 34 | Solute carrier family 25 member 34

Understanding SLC25A34: Potential Drug Targets for A Variety of Diseases

SLC25A34 is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a member of the SLC family of transmembrane proteins, which are characterized by the presence of a sulfate ion in the extracellular portion of the protein.

SLC25A34 is involved in a variety of physiological processes in the body, including cellular signaling, neurotransmitter transport, and regulation of ion channels. It has also been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and chronic kidney disease.

Due to its involvement in so many different processes in the body, SLC25A34 has been identified as a potential drug target. Researchers are currently working to develop small molecules that can inhibit the activity of SLC25A34 and treat a variety of diseases.

One of the challenges in studying SLC25A34 is its complex structure. Despite its prevalence in many different tissues, the exact layout of its transmembrane domains is not well understood. This lack of information can make it difficult to design small molecules that specifically target SLC25A34.

To overcome this challenge, researchers have used a variety of techniques to study the structure and function of SLC25A34. One of the most useful tools for this work has been biochemical assays, which allow researchers to study the interactions between SLC25A34 and other proteins.

In addition to these biochemical assays, researchers have also used techniques such as mass spectrometry and computer-based modeling to study the structure of SLC25A34. These studies have led to a greater understanding of the transmembrane structure of SLC25A34 and the regions that are involved in its function.

Based on these studies, researchers have identified several potential sites on SLC25A34 that could be targeted by small molecules. These sites include the N-terminus, the S1 loop, and the N- and C-termini.

One of the most promising targets for SLC25A34 is the N-terminus, which is known to be involved in the formation of the protein-protein interaction network. Researchers have identified several small molecules that can bind to this region and are currently working to determine their efficacy.

Another potential target for SLC25A34 is the S1 loop, which is known to be involved in the regulation of ion channels. Researchers have identified several small molecules that can bind to this region and are currently working to determine their effects on ion channels.

In addition to these targets, researchers are also studying the effects of small molecules on the activity of SLC25A34 in cell culture models of various diseases. These studies are providing valuable insights into the mechanisms of SLC25A34's function and the potential of small molecules as therapeutic agents.

While the development of small molecules that can inhibit the activity of SLC25A34 is an promising area of research, there are also concerns about the potential side effects of these molecules. For example, since SLC25A34 is involved in a variety of physiological processes in the body, it is possible that small molecules that inhibit its activity could have unintended consequences.

To address these concerns, researchers are currently working to develop SLC25A34-specific inhibitors that can be tested in animal models of disease. These inhibitors will be carefully designed to minimize their potential for side effects and will be tested for their safety and efficacy.

Overall, SLC25A34 is a protein that has significant involvement in a variety of physiological processes in the body, and its potential as a drug target is a promising area of research. While further studies are needed to fully understand its mechanisms of function and potential as a therapeutic agent, the development of small molecules that can inhibit its activity is an promising step forward in the search for new treatments for a variety of diseases.

Protein Name: Solute Carrier Family 25 Member 34

The "SLC25A34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets